RhumbLine Advisers’s Surface Oncology, Inc. Common Stock SURF Stock Holding History

RhumbLine Advisers’s Portfolio SURF Stock Details SURF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-41,388	Closed	-$122K	–	3295
2022 Q1	$122K	Sell	41,388 -4,055	-9%	-$14.2K	﹤0.01%	2852
2021 Q4	$217K	Sell	45,443 -845	-2%	-$5.45K	﹤0.01%	2816
2021 Q3	$350K	Buy	46,288 +1,850	+4%	+$11.8K	﹤0.01%	2699
2021 Q2	$332K	Buy	+44,438	New	+$342K	﹤0.01%	2748
2019 Q2	–	Sell	-11,297	Closed	-$54K	–	3020
2019 Q1	$54K	Buy	+11,297	New	+$55.6K	﹤0.01%	2915

Other funds holding SURF

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RhumbLine Advisers's SURF Position: Q2 2022 in Review

RhumbLine Advisers sold out of Surface Oncology, Inc. Common Stock (SURF) in Q2 2022, closing a stake of 41,388 shares — an estimated $122K sold.

RhumbLine Advisers first reported a position in SURF in Q1 2019 and held it in 5 quarters. The position peaked at $350K in Q3 2021. 84 funds tracked by Wall St. Rank hold SURF as of Q2 2022.

RhumbLine Advisers reported no remaining Surface Oncology, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
RhumbLine Advisers sold 41,388 Surface Oncology, Inc. Common Stock shares in Q2 2022, an estimated $122K.
RhumbLine Advisers first reported a position in Surface Oncology, Inc. Common Stock in Q1 2019 and held it in 5 quarters.
RhumbLine Advisers's Surface Oncology, Inc. Common Stock position peaked at $350K in Q3 2021.
84 funds tracked by Wall St. Rank held Surface Oncology, Inc. Common Stock as of Q2 2022.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.